July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
September 01, 2021 19:45 ET | The Rosen Law Firm PA
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
August 23, 2021 17:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
July 29, 2021 17:00 ET | Cyclerion Therapeutics, Inc.
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive...
logo.png
Multi-Site Contributor Headlands Research Congratulates Biogen on FDA Approval of Aducanumab for Alzheimer’s Disease
June 16, 2021 09:00 ET | Headlands Research
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- Headlands Research (www.headlandsresearch.com), a global next-generation clinical research site organization, is pleased to have supported Biogen...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board
April 20, 2021 11:31 ET | Cognition Therapeutics, Inc.
Pittsburgh, April 20, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage...
ARC logo.png
Alzheimer’s Disease Treatment Market Value Predicted To Reach US$ 5,647.5 Million By 2027: Acumen Research And Consulting
April 07, 2021 10:12 ET | Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Alzheimer’s Disease Treatment Market– Global Industry Analysis, Market Size,...
Research Nester  Logo
Global Alzheimer’s Treatment Market to Touch USD 2008.17 Million in 2027; Alzheimer’s Treatment Market in North America to Bring in Highest Revenue of around USD 500 Million in 2020
November 02, 2020 08:20 ET | Research Nester
New York, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Causing disability majorly among older people, Alzheimer’s disease contributes to 60-70% of dementia cases, currently amounting to around 50 million cases...
Logo.png
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
October 13, 2020 09:30 ET | Processa Pharmaceuticals, Inc.
HANOVER, Md, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics Appoints Industry Veteran Jack Khattar to its Board of Directors
September 09, 2020 08:00 ET | Cognition Therapeutics, Inc.
Pittsburgh, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
ImmunoBrain Checkpoint logo.jpg
ImmunoBrain Checkpoint awarded Alzheimer’s Association grant to support Phase I trial investigating novel immunotherapeutic approach to treat Alzheimer’s disease
September 01, 2020 07:06 ET | ImmunoBrain Checkpoint
ImmunoBrain Checkpoint awarded Alzheimer’s Association grant to support Phase I trial investigating novel immunotherapeutic approach to treat Alzheimer’s disease NEW YORK, Tuesday September 1, 2020...